XENE Form 144: 270,000 Shares via Option Exercise

XENE files a Form 144 reporting the proposed sale of 270,000 common shares through the exercise of options on 03/09/2026.

Rhea-AI Filing Summary

XENE files a Form 144 reporting the proposed sale of 270,000 common shares through the exercise of options on 03/09/2026. The filing also records a prior sale of 40,000 common shares by Ian Mortimer on 01/02/2026 and shows 1,777,166 shares associated with that holder.

Insights

Insider Transactions Analyst

Routine insider resale notice; volume is disclosed.

The filing lists a proposed sale of 270,000 common shares via exercise of options on 03/09/2026. It also records a prior sale of 40,000 common shares by Ian Mortimer on 01/02/2026.

Transaction timing and consideration are explicit: the method is an option exercise with cash indicated. Cash‑flow treatment beyond that and post‑transaction ownership levels are not further detailed in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does XENE's Form 144 report on 03/09/2026?

It reports a proposed sale of 270,000 common shares by exercise of options on 03/09/2026. The filing specifies the method as an exercise of options and indicates cash as consideration.

Who sold shares in the past three months according to the filing for XENE?

The filing lists Ian Mortimer as selling 40,000 common shares on 01/02/2026. The entry includes a share figure of 1,777,166 associated with that line in the excerpt.

Does the Form 144 show how the proceeds will be used for XENE?

The excerpt indicates the transaction method as cash for the option exercise. It does not provide any further detail on use of proceeds or allocation in the provided text.

Are the securities being sold by XENE registered or issuer-led?

The filing describes the sale as occurring via an exercise of options and lists the issuer in the related field. The excerpt identifies the method and the 270,000 share quantity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/09/2026 - 04:46 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001619961
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Xenon Pharmaceuticals Inc.
SEC File Number	001-36687
Address of Issuer	3650 Gilmore Way Burnaby BRITISH COLUMBIA, CANADA V5G 4W8
Phone	(604)-484-3300
Name of Person for Whose Account the Securities are To Be Sold	IAN MORTIMER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Canaccord Genuity Corp. 1133 Melville St Suite 1200 Vancouver, BC Z4 V6E 4E5	270000	16289196	83190316	03/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	03/09/2026	Exercise of Options	Issuer			270000	03/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ian Mortimer 3650 Gilmore Way Burnaby A1 V5G 4W8	Common Shares	01/02/2026	40000	1777166

144: Remarks and Signature

Remarks	The Common Shares reported on this Form 144 were obtained via the exercise of options scheduled to expire between March 12, 2027 and September 15, 2029, and are being sold pursuant to a Rule 10b5-1 trading plan.
Date of Notice	03/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/27/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ian Mortimer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)